Skip to content

Released Nov 5, 2026, before the open

10-Q filed Nov 5, 2026, 36 days after period end · 0001628280-26-070521

Q3 2026 · 10-Q
Revenue$107.65M−6.7% vs Q3 2025+1.8% vs Q2 2026
Net Income-$46.14MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$0.04N/M vs Q3 2025N/M vs Q2 2026
Operating Income-$62,978,000N/M
Operating Cash Flowderived-$57,868,000N/M
Free Cash Flowderived-$58,815,000N/M
Margins · derived
Operating margin-58.5%−16.2 pt vs Q3 2025
Net margin-42.9%−11.7 pt vs Q3 2025

What the release said

On November 5, 2026, Zai Lab Limited issued a press release announcing its financial results for the third quarter of 2026.

Total revenue was $108.2 million in the third quarter of 2026, compared to $116.1 million for the same period in 2025.2

Net loss was $46.1 million in the third quarter of 2026, or $0.04 per ordinary share, compared to a net loss of $36.0 million, or $0.03 per ordinary share, in 2025.3

On October 22, 2026, the Company agreed to sell 11,340,000 ADSs at $22.04 per ADS in a private placement that closed on October 27, 2026, with net proceeds of approximately $241.2 million.4

Cash and cash equivalents, current restricted cash, and short-term investments totaled $659.7 million as of September 30, 2026, compared to $717.5 million as of June 30, 2026.5

Zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% and an estimated 6-month PFS rate of 81.9% among 33 efficacy evaluable patients, and Zai Lab is advancing it into a global Phase 3 study.6

Total revenue
$108.2 million Third quarter of 2026, compared to $116.1 million for the same period in 20252
Net loss
$46.1 million Third quarter of 2026, compared to $36.0 million for the same period in 20253
Loss per ordinary share
$0.04 Third quarter of 2026, compared to $0.03 for the same period in 20253
Cash, restricted cash and short-term investments
$659.7 million As of September 30, 2026, compared to $717.5 million as of June 30, 20265
Inventory write-downs
$13.6 million Cited as the primary driver of the increase in net loss in 20263
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Revenue$107.65M$115.36M$101.85M$69.23M
Net Income-$46.14M-$35.96M-$41.67M-$69.15M
EPS Diluted-$0.04-$0.03-$0.04-$0.07

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Zai Lab Ltd · CIK 1704292 · Engraved from SEC EDGAR